Sellas Life Sciences Group Inc (SLS) - News Archive

Acute Myeloid Leukemia (AML) is a severe hematologic malignancy impacting both adults and children. The pediatric variant of AML tends to have unique genetic features and treatment challenges. Recent progress in targete...

Emergence of SLS009 and Galinpepimut-S: Targeted Therapeutics in the Fight Against Relapsed and Refractory Acute Myeloid Leukemia and Solid Tumors The landscape of cancer treatment is evolving with the advent of targete...

Interim Analysis Triggered in Phase 3 REGAL Trial of GPS in Acute Myeloid Leukemia by SELLAS Life Sciences SELLAS Life Sciences Group Inc. (NASDAQ: SLS) has announced the initiation of an interim analysis in its Phase 3...

Potential Role of SLS009 in Oncological Therapeutics: Insights From Preclinical and Clinical Trials The exploration of novel therapeutic agents in the field of oncology has seen significant advancements in recent years....

Recent announcements from SELLAS Life Sciences Group Inc. have spotlighted its asset, Galinpepimut-S (GPS), which has received the U.S. FDA s Rare Pediatric Disease Designation (RPDD) for treating pediatric acute myeloi...

SELLAS Life Sciences Group Announces Registered Direct Offering to Support Cancer Therapy DevelopmentSELLAS Life Sciences Group, Inc. (NASDAQ: SLS), a pioneering biopharmaceutical company specializing in cancer therapie...

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS), a leading clinical biopharmaceutical company specializing in the development of advanced therapies for various cancer indications, recently announced a significant achieve...

Acute Lymphoblastic Leukemia (ALL) is the most common type of cancer affecting children and poses significant challenges in terms of treatment options. However, SELLAS Life Sciences has recently made significant progres...

SELLAS Life Sciences has recently announced the completion of enrollment and initial positive data in the Phase 2a trial of SLS009 in patients with relapsed or refractory acute myeloid leukemia (r/r AML). The trial, whi...

SELLAS Life Sciences Group recently unveiled encouraging preliminary results from their Phase 2 study of SLS009 in patients with relapsed/refractory acute myeloid leukemia (r/r AML) who carry the ASXL1 mutation. The stu...

SELLAS Life Sciences, a late-stage clinical biopharmaceutical company specializing in cancer therapies, recently made several significant announcements. The company received a positive recommendation from the Independen...

SELLAS Announces Promising Data from Phase 2a Study of SLS009 in Relapsed/Refractory AML and Receives FDA Fast Track DesignationSELLAS Life Sciences Group, Inc. (NASDAQ: SLS), a leading clinical biopharmaceutical compan...

SELLAS Life Sciences Group Successfully Closes $20 Million Offering, Accelerating Cancer Therapies DevelopmentNEW YORK, March 19, 2024 - Leading biopharmaceutical company, SELLAS Life Sciences Group, Inc. (NASDAQ: SLS),...

In a significant move for SELLAS Life Sciences Group, Inc., the company has announced that it has entered into definitive agreements with two existing institutional investors for the purchase and sale of over 13 million...

Sellas Life Sciences Group, a renowned late-stage clinical biopharmaceutical company dedicated to developing innovative therapies for a wide range of cancer indications, has recently announced a strategic reorganization...

SELLAS Life Sciences Presents SLS009 Phase 1 Data for Acute Myeloid Leukemia at ESH ConferenceSELLAS Life Sciences Group, Inc. (NASDAQ: SLS), a leading clinical biopharmaceutical company dedicated to developing innovati...

:The development of novel therapies for the treatment of cancer is a critically important area of research. In particular, hematologic malignancies pose a significant challenge due to their complex nature and limited tr...

Acute myeloid leukemia (AML) is a challenging and aggressive form of blood cancer that requires effective treatment options. SELLAS Life Sciences recently received Fast Track Designation from the FDA for SLS009, a poten...

NEW YORK, Jan. 03, 2024 - SELLAS Life Sciences Group, Inc. (NASDAQ: SLS), a prominent late-stage clinical biopharmaceutical company specializing in developing innovative cancer therapies, has unveiled its plans to offer...

SELLAS Life Sciences Group, a late-stage clinical biopharmaceutical company, is known for its pioneering focus on the development of novel cancer immunotherapies. It is a significant contributor to the field of medicine...